WallStreetZenWallStreetZen

NYSEMKT: KAPA
Kairos Pharma Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KAPA

Based on 1 analyst offering 12 month price targets for Kairos Pharma Ltd

Min Forecast
$9.00+1,530.43%
Avg Forecast
$9.00+1,530.43%
Max Forecast
$9.00+1,530.43%

Should I buy or sell KAPA stock?

Based on 1 analyst offering ratings for Kairos Pharma Ltd.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KAPA stock forecasts and price targets.

KAPA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-19

1 of 1

Forecast return on equity

Is KAPA forecast to generate an efficient return?

Company
-130.88%
Industry
64.47%
Market
171.75%
KAPA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KAPA forecast to generate an efficient return on assets?

Company
-126.9%
Industry
30.51%
KAPA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KAPA earnings per share forecast

What is KAPA's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.35
Avg 2 year Forecast
-$0.51
Avg 3 year Forecast
-$0.54

KAPA revenue forecast

What is KAPA's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

KAPA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KAPA$0.55$9.00+1,530.43%Strong Buy
CURX$0.41N/AN/A
BIVI$1.58N/AN/A
GDTC$0.99N/AN/A
AKTX$5.24$33.50+539.31%Strong Buy
View Top Biotech Stocks

Kairos Pharma Stock Forecast FAQ

Is Kairos Pharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: KAPA) stock is to Strong Buy KAPA stock.

Out of 1 analyst, 1 (100%) are recommending KAPA as a Strong Buy, 0 (0%) are recommending KAPA as a Buy, 0 (0%) are recommending KAPA as a Hold, 0 (0%) are recommending KAPA as a Sell, and 0 (0%) are recommending KAPA as a Strong Sell.

If you're new to stock investing, here's how to buy Kairos Pharma stock.

What is KAPA's earnings growth forecast for 2026-2028?

(NYSEMKT: KAPA) Kairos Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.3%.

Kairos Pharma's earnings in 2026 is -$5,447,000.On average, 5 Wall Street analysts forecast KAPA's earnings for 2026 to be -$7,571,000, with the lowest KAPA earnings forecast at -$7,973,530, and the highest KAPA earnings forecast at -$7,418,980. On average, 5 Wall Street analysts forecast KAPA's earnings for 2027 to be -$10,992,509, with the lowest KAPA earnings forecast at -$14,058,593, and the highest KAPA earnings forecast at -$9,442,338.

In 2028, KAPA is forecast to generate -$11,647,692 in earnings, with the lowest earnings forecast at -$15,317,571 and the highest earnings forecast at -$8,992,703.

What is KAPA's revenue growth forecast for 2026-2028?

(NYSEMKT: KAPA) Kairos Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.

Kairos Pharma's revenue in 2026 is $0.On average, 5 Wall Street analysts forecast KAPA's revenue for 2026 to be $0, with the lowest KAPA revenue forecast at $0, and the highest KAPA revenue forecast at $0. On average, 5 Wall Street analysts forecast KAPA's revenue for 2027 to be $0, with the lowest KAPA revenue forecast at $0, and the highest KAPA revenue forecast at $0.

In 2028, KAPA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is KAPA's forecast return on assets (ROA) for 2026-2029?

(NYSEMKT: KAPA) forecast ROA is -126.9%, which is lower than the forecast US Biotechnology industry average of 30.51%.

What is KAPA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year KAPA price target, the average KAPA price target is $9.00, with the highest KAPA stock price forecast at $9.00 and the lowest KAPA stock price forecast at $9.00.

The Wall Street analyst predicted that Kairos Pharma's share price could reach $9.00 by Nov 19, 2026. The average Kairos Pharma stock price prediction forecasts a potential upside of 1,530.43% from the current KAPA share price of $0.55.

What is KAPA's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSEMKT: KAPA) Kairos Pharma's current Earnings Per Share (EPS) is -$0.30. On average, analysts forecast that KAPA's EPS will be -$0.35 for 2026, with the lowest EPS forecast at -$0.37, and the highest EPS forecast at -$0.35. On average, analysts forecast that KAPA's EPS will be -$0.51 for 2027, with the lowest EPS forecast at -$0.66, and the highest EPS forecast at -$0.44. In 2028, KAPA's EPS is forecast to hit -$0.54 (min: -$0.72, max: -$0.42).

What is KAPA's forecast return on equity (ROE) for 2026-2029?

(NYSEMKT: KAPA) forecast ROE is -130.88%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.